the recent fda approval of isavrd for transplant-ineligible newly diagnosed myeloma
Published 1 month ago • 67 plays • Length 0:40Download video MP4
Download video MP3
Similar videos
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
0:44
the recent fda approval of ponatinib for ph all following success in the phallcon trial
-
1:25
recent fda approval of exa-cel & lovo-cel for patients with scd
-
0:45
fda approval of teclistamab for r/r multiple myeloma and the value of immunotherapies
-
2:27
milestone trial results: mrd response-adapted deferral of autosct in newly diagnosed myeloma
-
1:26
mrd in myeloma: the fda perspective
-
21:38
drawing the line: the rationale behind blood tube collection order
-
3:16
end stage multiple myeloma
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
1:23
the association between mrd and pfs in myeloma
-
1:53
the future of multiple myeloma treatment
-
2:17
extended follow-up of the master trial
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
1:05
the role of imaging in myeloma diagnosis and in assessing treatment response
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
1:05
an overview of the radar trial
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
1:34
sequencing of agents in lr-mds